Compare SiTime Corporation (SITM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs GeneDx Holdings Corp — how do they compare? SiTime Corporation trades at $588 (market cap $18.03B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: SiTime Corporation is far larger — about 7× GeneDx Holdings Corp's market cap, and SiTime Corporation is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| SITM | WGS | |
|---|---|---|
Market Cap | $18.03B | $2.56B |
Sector | Technology | Technology |
52-Week High | $901.60 | $167.51 |
52-Week Low | $245.57 | $34.51 |
Enterprise Value | $17.43B | $2.60B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SITM trades at $598.95, down 2.15% today, but maintains strong analyst support with 9 unanimous buy ratings and a $863.33 consensus price target representing 44% upside. The stock shows bullish technical signals despite recent weakness, with support at $584 and resistance at $627. Recent Q2 2026 earnings beat expectations with $2.34 EPS versus $1.95 expected, driven by 127% revenue growth and AI infrastructure demand.
The outlook remains positive with Q3 2026 guidance pointing to substantial growth following the Renesas acquisition. Key risks include high valuation multiples (P/E 999, P/S 34) and negative 2025 net income, though 2026 projections show profitability improvement. Institutional buying, including California State Teachers' 73,098.9% stake increase, supports the growth narrative.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
